Immutep’s Efti Combination Therapy Achieves Success in Phase II Soft Tissue Sarcoma Trial

Immutep Ltd ( (AU:IMM) ) has shared an update.

Immutep Limited announced that its EFTISARC-NEO Phase II trial, which evaluates the combination of eftilaginod alpha (efti) with radiotherapy and KEYTRUDA® in treating resectable soft tissue sarcoma, has successfully met its primary endpoint. The trial demonstrated a significant improvement in tumor hyalinization/fibrosis compared to historical data, suggesting enhanced efficacy in transforming the tumor microenvironment and addressing the high unmet need in this aggressive cancer. The results, which highlight the potential of efti in cancer treatment, are expected to be presented at a future medical meeting.

The most recent analyst rating on (AU:IMM) stock is a Buy with a A$0.92 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.

More about Immutep Ltd

Immutep Limited is a late-stage biotechnology company specializing in the development of novel immunotherapies for cancer and autoimmune diseases. The company is a leader in the research and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), focusing on leveraging this expertise to provide innovative treatment options and maximize shareholder value.

YTD Price Performance: -19.18%

Average Trading Volume: 4,304,154

Technical Sentiment Signal: Sell

Current Market Cap: A$430.8M

Learn more about IMM stock on TipRanks’ Stock Analysis page.